rAAV information: summary table of the Cre-dependent rAAVs used in the present study
| Construct | Serotype | Titer | Injection volume | Vendor | Figures |
|---|---|---|---|---|---|
| AAV-EF1a-DIO-eYFP | 5 | ≥4 × 1012 vg/ml | 0.2 μl/site | UNC Core | 1, 2, 4, 5, Extended Data 4–1, Extended Data 4–2 |
| AAV-EF1a-DIO-mCherry | 5 | ≥7 × 1012 vg/ml | 0.2 μl/site | UNC Core | 1, 2, 3, 8, 3–1, Extended Data 4–1, Extended Data 4–2 |
| AAV-hSyn-DIO-hM3D(Gq)- mCherry | 8 | ≥5 × 1012 vg/ml | 0.2 μl/site | UNC Core | 6, 8, Extended Data 6–1 |
| AAV-hSyn-DIO-hM4D(Gi)- mCherry | 5 | ≥8 × 1012 vg/ml | 0.2 μl/site | Addgene (catalog #44362) | Extended Data 6–2 |
Overall, four Cre-dependent constructs were used that differed by promoter (EF1a, hSyn), serotype (AAV5, AAV8), and/or vendor (UNC Core, Addgene). High-titer (≥4 × 1012 vg/ml) stock virus (0.2 μl) was injected into each region of interest.